Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Asthma (13)
  • x Basic immunology (1)
  • Biologicals (10)
  • Biomarkers (6)
  • COVID19 (1)
  • x Drug allergy (3)
  • ENT (5)
Poster available until
Poster categories
  • Thematic Poster Session (1)
keywords
Session Reference
  • L-TPS01 (6)
  • L-TPS02 (2)
  • L-TPS05 (12)
  • L-TPS07 (1)
  • L-TPS09 (2)
  • L-TPS12 (11)
  • L-TPS13 (4)
  • L-TPS14 (6)
  • L-TPS15 (2)
  • L-TPS18 (1)
  • L-TPS21 (12)
  • TPS02 (2)
  • TPS03 (3)
  • TPS09 (3)
  • TPS11 (13)
  • TPS12 (12)
  • TPS14 (2)
  • TPS17 (9)
  • TPS28 (3)
  • TPS31 (3)
  • TPS36 (12)
  • TPS37 (4)
  • TPS38 (6)
  • TPS41 (9)
  • TPS52 (5)
  • TPS53 (6)
  • TPS54 (15)
  • x TPS55 (4)
  • TPS57 (1)
  • TPS61 (11)
  • TPS62 (9)
  • TPS63 (9)
  • TPS66 (9)
  • TPS67 (1)
  • TPS69 (1)
4 results
Thumbnail

- D3.103 - Impact of aspirin-induced bronchospasm on the in vitro Aspirin Hypersensitivity Diagnostic Index in the patients with Aspirin Exacerbated Respiratory Disease

Thumbnail

D3.109 - Lichen planus following dupilumab treatment in patients with severe asthma and nasal sinus polyposis

Thumbnail

- D3.110 - Contribution of biotherapies in the reintroduction of NSAIDs in patients with moderate to severe asthma, hypersensitive to COX-1 inhibitor NSAIDs

Thumbnail

- D3.113 - In silico system pharmacology modeling provides insights into a mechanism for greater potency of TSLP/TSLPR pathway inhibition with verekitug, a novel antibody antagonist of TSLPR, as compared to tezepelumab

Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM